Phaseline

Companies › Evopoint Biosciences

Evopoint Biosciences: clinical trials, targets and expected readouts

3 active drug programs in 6 registered trials: 3 Phase 1, 2 Phase 3, 1 Phase 2; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
XNW28012 for Injection–Phase 3Pancreatic Cancer; Advanced Solid TumorsDec 2026
XNW5004 tablets
EZH2 inhibitor
EZH2Phase 3Relapsed/Refractory Peripheral T Cell Lymphoma; Follicular Lymphoma, Grade 1; Metastatic Castrate-Resistant Prostate CancerJul 2027
XNW29016
PARG inhibitor
PARGPhase 1Tumor, SolidFeb 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06799637XNW28012 for InjectionPhase 1Advanced Solid TumorsOncologyDec 2026
NCT06987500XNW29016Phase 1Tumor, SolidOncologyFeb 2027
NCT07823049XNW28012 for InjectionPhase 3Pancreatic CancerOncologyMay 2027
NCT06702995XNW5004 tabletsPhase 1Metastatic Castrate-Resistant Prostate CancerOncologyJul 2027
NCT07545603XNW5004 tabletsPhase 2Follicular Lymphoma, Grade 1OncologyDec 2027
NCT06776952XNW5004 tabletsPhase 3Relapsed/Refractory Peripheral T Cell LymphomaOncologyJan 2028

Targets

PARG (1) EZH2 (1)

Companies with the same targets

FoRx Therapeutics 858 Therapeutics IDEAYA Biosciences Novartis Epizyme Daiichi Sankyo Hanmi Pharmaceutical Company

Companies built like this

Guangzhou Gloria Biosciences Nuvation Bio Allist Pharmaceuticals Shanghai Kechow Pharma Dizal Pharmaceuticals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.